Ledraxen (Enoxaparin Sodium)

Ledraxen, a low molecular weight heparin, is indicated for several thromboembolic conditions.

• Deep vein thrombosis: prevents clot formation and treats existing DVT in at‑risk patients, reducing the chance of vein obstruction and post‑thrombotic syndrome.
• Pulmonary embolism: reduces risk of embolic events and treats confirmed PE, helping to restore pulmonary circulation and improve oxygenation.
• Hemodialysis anticoagulation: maintains circuit patency by preventing clotting during dialysis sessions, allowing effective blood purification without interruption.

• Enoxaparin sodium binds to antithrombin III, accelerating its inhibition of activated factor Xa and, to a lesser extent, thrombin (factor IIa). By selectively blocking factor Xa, the cascade that generates fibrin is disrupted, leading to reduced clot formation. Its enhanced antithrombin activity provides a predictable anticoagulant response with a lower risk of platelet activation compared with unfractionated heparin. Its pharmacokinetic profile allows once‑ or twice‑daily dosing without routine laboratory monitoring in most patients.

Enoxaparin sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site pain or erythema
• Minor bruising or hematoma at injection site
• Nausea or mild gastrointestinal upset
• Headache
• Elevated liver enzymes

Serious or Rare Side Effects

• Major bleeding, including intracranial or gastrointestinal hemorrhage
• Heparin‑induced thrombocytopenia (HIT)
• Spinal or epidural hematoma, especially after neuraxial procedures
• Severe allergic reactions such as anaphylaxis

When using Ledraxen, clinicians should observe specific precautions to minimize risk and ensure efficacy.

• Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function.
• Concomitant anticoagulants: avoid or closely monitor use with warfarin, direct thrombin inhibitors, or antiplatelet agents.
• Surgery or invasive procedures: discontinue before major surgery to reduce bleeding risk.
• Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited.
• Platelet monitoring: check platelet counts regularly to detect heparin‑induced thrombocytopenia.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin sodium can interact with other medicines, affecting anticoagulant activity or bleeding risk.

Major Interactions (Avoid)

• Concurrent use with other anticoagulants (e.g., warfarin, dabigatran, rivaroxaban) may cause uncontrolled bleeding.
• Antiplatelet drugs (aspirin, clopidogrel, ticagrelor) increase hemorrhagic risk.
• Fibrinolytic agents (alteplase, streptokinase) potentiate anticoagulation.
• Neuraxial anesthesia or spinal puncture: heightened risk of spinal hematoma.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) can augment bleeding tendency.
• Selective serotonin reuptake inhibitors (SSRIs) may increase risk of gastrointestinal bleeding.
• Heparin products: combined use may trigger thrombocytopenia; monitor platelet counts.